Skip to main content
  • Acanthas Pharma, Inc.
  • Investment: 2020
  • Status: Exited

Acanthas Pharma, Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II SCSp.
Acanthas is developing an oral small molecule targeting a mutation involved in multiple cancers, in particular Acute Myeloid Leukemia, sarcomas and gliomas.

Involved Team

Dr. Luc Marengère
Managing Partner
Marc Rivière, MD
General Partner,

Dr. Cynthia Cardinal (CEO)